Glatt and Innopharma Labs Partner on Real-Time In-Line Particle Characterization for Batch and Continuous Production - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Glatt and Innopharma Labs Partner on Real-Time In-Line Particle Characterization for Batch and Continuous Production


Glatt and Innopharma Labs have formed a partnership to provide Glatt’s customers access to Innopharma Labs’ non-invasive, real-time 3D particle characterizer, Eyecon, which has the ability to generate live particle size and shape information.


Developed specifically for pharmaceutical processes, the particle characterizer increases process understanding, and subsequently control, in formulation development, scale up, tech transfers, and process optimization in commercial manufacturing of both batch and continuous processes, leading to a reduction of lead times.  


Eyecon is a self-contained portable image capture and analysis sensor that can be mounted to inspection ports of Glatt equipment for in-line, real-time, non-product contact monitoring of particle morphology and size to aid in reducing batch losses and cycle time, improving yields and gain greater control of process end points during granulation, coating, spheronization and continuous fluid bed drying. The imaging analysis collects relevant data for formulation development. Being captured in real-time data helps to gain maximal transparency in the production process for complete documentation.


Eyecon may also be used for static bench-top sample analysis. It can also support process analytical technology and continuous manufacturing of pharmaceutical products.


Source: PR Newswire

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here